ASP Isotopes (ASPI) is drawing fresh attention after short interest climbed to 21.49% of its tradable shares, far above the 5.41% peer average. This shift signals a sharper bearish stance among some investors.

At a share price of $7.51, ASP Isotopes has seen strong short term momentum, with a 1 month share price return of 26.43% and year to date share price return of 33.39%. The 1 year total shareholder return of 51.72% and very large 3 year total shareholder return suggest earlier investors have already experienced substantial swings in sentiment, especially as the 90 day share price return of a 46.55% decline sits alongside the recent completion of the Renergen deal and a sharp rise in short interest.

If ASPI's recent volatility has you thinking about diversification, this could be a good moment to broaden your watchlist with high growth tech and AI stocks.

With short interest high, a recent Renergen deal, and the shares trading at a discount to a US$13.00 price target, is ASP Isotopes still misunderstood value, or is the market already pricing in the next leg of growth?

Price to Book of 11.2x: Is It Justified?

ASP Isotopes last closed at US$7.51, and on a P/B basis it sits at 11.2x, far above both its industry and peer reference points.

The P/B ratio compares a company’s market value to its book value, which is essentially net assets on the balance sheet. For a development stage materials business with limited current earnings and a focus on specialized isotope technology, investors often lean on asset based and pipeline expectations rather than profit based metrics.

In this case, the P/B of 11.2x stands against a US Chemicals industry average of 1.4x and a peer average of 2.3x. That gap indicates the market is assigning a much richer valuation to ASP Isotopes equity than to typical chemical names, potentially reflecting expectations around future commercialisation of its nuclear fuels and specialist isotopes segments rather than current financial performance.

Result: Price-to-book of 11.2x (OVERVALUED)

However, that rich P/B sits alongside annual revenue of just US$8.38m and a net loss of US$105.56m, which could challenge any positive valuation narrative.

Another View, Our DCF Model Paints a Very Different Picture

While the 11.2x P/B ratio makes ASPI look expensive next to the US Chemicals industry at 1.4x and peers at 2.3x, our DCF model points the other way. It suggests fair value of US$79.94 per share versus the current US$7.51, which implies the stock trades at a very large discount. When one model flags rich pricing and another flags deep value, which set of assumptions do you trust more?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out ASP Isotopes for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 886 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own ASP Isotopes Narrative

If you look at these numbers and reach a different conclusion, or simply want to test your own assumptions, you can build a personalised ASP Isotopes story in just a few minutes: Do it your way.

A great starting point for your ASP Isotopes research is our analysis highlighting 3 key rewards and 4 important warning signs that could impact your investment decision.

Ready for more investment ideas?

If you are serious about broadening your opportunities, do not stop at one stock. These screeners can help you quickly spot ideas that match your style.

• Target higher potential upside with carefully filtered small companies by scanning these 3527 penny stocks with strong financials that already show stronger fundamentals.
• Ride the AI wave in a focused way by zeroing in on these 26 AI penny stocks that tie real business models to artificial intelligence themes.
• Hunt for mispriced opportunities by checking these 886 undervalued stocks based on cash flows that stand out on cash flow based metrics, before the crowd catches up.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.